EcoDrugPlus

Sodium Voltage-Gated Channel Alpha Subunit 3

Ensembl ID : ENSOPRG00000004253
Gene Symbol: SCN3A
1 Cross references
167 Possible Orthologues:

Sodium Voltage-Gated Channel Alpha Subunit 4

Ensembl ID : ENSOPRG00000015098
Gene Symbol: SCN4A
1 Cross references
193 Possible Orthologues:

Sodium Voltage-Gated Channel Alpha Subunit 5

Ensembl ID : ENSOPRG00000001094
Gene Symbol: SCN5A
1 Cross references
95 Possible Orthologues:

Sodium Voltage-Gated Channel Alpha Subunit 8

Ensembl ID : ENSOPRG00000017001
Gene Symbol: SCN8A
1 Cross references
274 Possible Orthologues:

Sodium Voltage-Gated Channel Alpha Subunit 9

Ensembl ID : ENSOPRG00000005900
Gene Symbol: SCN9A
1 Cross references
110 Possible Orthologues:

Solute Carrier Family 10 Member 2

Ensembl ID : ENSOPRG00000012296
Gene Symbol: SLC10A2
1 Cross references
214 Possible Orthologues:

Solute Carrier Family 18 Member A2

Ensembl ID : ENSOPRG00000012830
Gene Symbol: SLC18A2
3 Cross references
223 Possible Orthologues:

Solute Carrier Family 5 Member 1

Ensembl ID : ENSOPRG00000010458
Gene Symbol: SLC5A1
2 Cross references
250 Possible Orthologues:

Solute Carrier Family 5 Member 2

Ensembl ID : ENSOPRG00000001445
Gene Symbol: SLC5A2
3 Cross references
197 Possible Orthologues:

Solute Carrier Family 6 Member 1

Ensembl ID : ENSOPRG00000011932
Gene Symbol: SLC6A1
1 Cross references
264 Possible Orthologues:

Solute Carrier Family 6 Member 2

Ensembl ID : ENSOPRG00000002738
Gene Symbol: SLC6A2
1 Cross references
202 Possible Orthologues:

Solute Carrier Family 6 Member 3

Ensembl ID : ENSOPRG00000014617
Gene Symbol: SLC6A3
1 Cross references
166 Possible Orthologues:

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).